Webinars and Sponsored Roundtables — Register Now
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Werfen
| Company | Werfen |
|---|---|
| Name of instrument | BIO-FLASH |
| City, State | San Diego, CA |
| Phone | 858-586-9900 |
| Website | |
| Type of instrument | immunoassay |
| List price/First year sold in U.S. | —/2012 |
| Targeted hospital bed size/Targeted test volume | — |
| Company manufactures instrument | yes |
| Other models in this family of analyzers | — |
| No. of units in clinical use in U.S./Outside U.S. (countries) | —/1,000 |
| Dimensions (H × W × D)/Instrument footprint | 21 × 34 × 24 in./— |
| Weight empty/Weight fully loaded | 170 lbs./— |
| No. of different measured assays onboard simultaneously | 20 (20 can be run and calibrated at one time) |
| No. of user-definable (open chemistry) channels | 0 |
| Test throughput per hour/Assay run time | 60 (60 tests in throughput)/30 min. |
| No. of direct ion-selective electrode channels | — |
| Detection methods | — |
| Stat time until completion/specimen throughput for Ion-selective electrode | — |
| Stat time until completion/specimen throughput for Ion-selective electrode basic metabolic panel | — |
| Stat time until completion/specimen throughput for Ion-selective electrode complete metabolic panel | — |
| Typical time delay from ordering stat test until aspiration of sample | — |
| Fully automated microplate immunoassay system | no |
| Methodologies supported | chemiluminescence |
| Separation methodologies | magnetic particle, bead |
| Stat time until completion of a ß-hCG test | — |
| Stat time until completion of a cTn test | — |
| • Typical time delay from test order to aspiration of sample | — |
| Reagents refrigerated onboard/Reagents ready to use | yes/yes |
| Reagent lot tracking/Reagent inventory | yes/yes |
| Reagent form/Reagents barcoded | liquid chemistry (closed reagent system)/yes |
| Separate reagent pack for each specimen/for each test run | no/yes |
| Walkaway capability/Walkaway duration | yes/30 specimens or 140 tests |
| Design of sample-handling system | rack |
| Uses washable cuvettes/Uses disposable cuvettes | no/yes (can store up to 280 cuvettes) |
| Min.–max. sample volume that can be aspirated at one time | 4–250 µL |
| Min. reaction volume/Min. specimen volume/Min. dead volume | 20 µL/5 µL/200 µL |
| Dedicated pediatric sample cup | yes |
| Primary tube sampling | yes |
| Accommodates most standard tube sizes/Accepts nonstandard tube sizes | yes/no |
| Pierces caps on primary tubes | no |
| Protects against probe collision | no |
| Detects clots/liquid level/short sample | yes/yes/yes |
| Detection or quantitation for hemolysis, icterus, lipemia, clots | — |
| Dilutes patient samples onboard/Susceptibility to carryover | yes (can be programmed to perform dilutions prior to analysis)/— |
| Automatic rerun capability | yes |
| Sample volume can be diluted to rerun out-of-linear-range high results | yes |
| Sample volume can be concentrated to rerun out-of-linear-range low results | no |
| Autocalibration/Multipoint calibration supported | no (calibrants are not stored onboard)/yes |
| Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays | —/—/—/—/once per year |
| Automatic programmable start/Automatic programmable shutdown | yes (5 min. warm-up time)/yes |
| Onboard real-time QC/Onboard software capability to review QC | yes/yes |
| Supports multiple QC lot numbers per analyte | no |
| Waste management | automated collection onboard instrument or direct to drain |
| Sample barcode-reading capability/Autodiscrimination | yes (Interleaved 2 of 5, Codabar, Code 39, Code 128)/yes |
| Lab can control analyzer from remote computer | no |
| Instrument can diagnose its own malfunctions | no (operator intervention required to order parts) |
| System malfunctions can be diagnosed via remote monitoring | no |
| UPS backup power supply | yes |
| Data-management capability/LIS or EHR systems interfaced | onboard/— |
| LIS interface provided/Bidirectional interface capability | no/yes (broadcast download and host query) |
| Modem servicing provided/Service engineer on-site response time | no/24 hrs. |
| Mean time between failures | — (displays error codes for troubleshooting) |
| Average scheduled maintenance time by lab personnel | daily: performed automatically; weekly: 5 min.; monthly: 15 min. |
| Maintenance records kept onboard for user/vendor | some records/some records |
| Maintenance training demonstration module onboard | no |
| Training included with purchase/Avg. time for basic user training | yes/3 hrs. (at customer site) |
| Advanced operator training/Extra charge for follow-up or advanced training | yes (at customer or vendor site)/— |
| Warranty provided/Cost of annual service contract (24 h/7 d) | yes/— |
| Distinguishing features (supplied by company) | improves laboratory workflow and productivity; eliminates batching and reagent waste with stable onboard reagents; provides simultaneous random-access processing of all isotypes and assays from one sample on a single run; delivers results, including stat orders, in as little as 30 minutes; minimal hands-on time for user maintenance |
| Note | all information listed was provided to CAP TODAY in 2025; company did not provide updated information by 2026 entry deadline |